SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address Ugwumba Chio | 1 0 | | 2. Issuer Name and Ticker or Trading Symbol BiomX Inc. [PHGE] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | | | |
|--|----------------|----------|---|--|--|--|--|--|--|--|
| (Last) 609 SW 8TH STR | (First) EET | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 08/10/2022 | Officer (give title X Other (specify below) Exit Form 4 - former 10% owner | | | | | | |
| SUITE 365 | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) BENTONVILLE | AR | 72712 | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | |
| (City) | (State) | (Zip) | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | |
| | | | | | | | | | | |

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership | |
|---------------------------------|--|---|---|---|--|---------------|---------|--|---|---|--|
| | | | Code | v | Amount | (A) or (D) | Price | · Transaction(s) (Instr. 3 and 4) | | (Instr. 4) | |
| Common Stock | 08/10/2022 | | s | | 17,769 | D | \$0.74 | 3,620,077(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/11/2022 | | s | | 9,824 | D | \$0.744 | 3,610,253(1) | I | By Symbiosis, LLC | |
| Common Stock | 08/12/2022 | | S | | 11,406 | D | \$0.734 | 3,598,847(1) | I | By Symbiosis, LLC | |
| Common Stock | 08/15/2022 | | S | | 7,200 | D | \$0.747 | 3,591,647(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/16/2022 | | S | | 8,563 | D | \$0.729 | 3,583,084(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/17/2022 | | S | | 21,335 | D | \$0.688 | 3,561,749(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/18/2022 | | S | | 7,764 | D | \$0.683 | 3,553,985(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/19/2022 | | S | | 14,600 | D | \$0.639 | 3,539,385(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/22/2022 | | s | | 5,000 | D | \$0.657 | 3,534,385(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/23/2022 | | s | | 5,900 | D | \$0.638 | 3,528,485(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/24/2022 | | s | | 8,665 | D | \$0.652 | 3,519,820(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/25/2022 | | s | | 26,945 | D | \$0.718 | 3,492,875 | I | By SymBiosis, LLC | |
| Common Stock | 08/26/2022 | | S | | 60,628 | D | \$0.616 | 3,432,247(1) | I | By SymBiosis, LLC | |
| Common Stock | 08/29/2022 | | S | | 11,533 | D | \$0.571 | 3,420,714(1) | I | By SymBiosis, LLC | |

| | | Та | ble I - Non- | Derivative \$ | Securities Acc | uired, | Dis | posed of, | or Benef | icially Ov | wned | | | | |
|--|---|--|---|---------------------------------------|---|--|---------|------------------------------|---|-------------|---|---|--|---|--|
| 1. Title of Security (Instr. 3) | | | Da | Transaction ate lonth/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Disposed Of | | | 5. Amount of Securities Beneficially Owr Following Repor | 6. Ownership Form: Direct (D) or Indirect (I) orted (Instr. 4) | : Direct (D) lirect (I) | 7. Nature of Indirect Beneficial Ownership | |
| | | | | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) | |
| Common Stock | | | | 08/30/2022 | | s | | 13,487 | D | \$0.566 | 3,407,227(1 | 1) | I | By SymBiosis LLC | |
| Common Stock | | | 08/31/2022 | | s | | 4,540 | D | \$0.549 | 3,402,687(1 | I) | I | By SymBiosis LLC | | |
| Common Stock | | | 09/01/2022 | | s | | 8,297 D | | \$0.546 | 3,394,390(1 | I) | I | By SymBiosis LLC | | |
| Common Stock | | | 09/02/2022 | | s | | 2,001 | D | \$0.546 | 3,392,389(1 | l) | I | By SymBiosis LLC | | |
| Common Stock | | | 09/06/2022 | | s | | 6,403 | D | \$0.545 | 3,385,986(1 | 1) | I | By SymBiosis LLC | | |
| Common Stock | | | 09/07/2022 | | s | | 8,846 | D | \$0.528 | 3,377,140(1 | 1) | I | By SymBiosis LLC | | |
| Common Stock | | | 09/08/2022 | | s | | 4,592 | D | \$0.522 | 3,372,548(1 | 1) | I | By SymBiosis LLC | | |
| Common Stock | | | 09/09/2022 | | s | | 13,219 | D | \$0.518 | 3,359,329(1 | 1) | I | By SymBiosis LLC | | |
| Common Stock | | | 09/12/2022 | | s | | 1,700 | D | \$0.541 | 3,357,629(1 | 1) | I | By SymBiosis LLC | | |
| Common Stock | | | | 09/13/2022 | | s | | 2,201 | D | \$0.525 | 3,335,428(1 | 1) | I | By SymBiosis LLC | |
| Common Stock | | | | 09/14/2022 | | s | | 2,301 | D | \$0.523 | 3,353,127(1 | I) | I | By SymBiosis LLC | |
| Common Stock | | | | 09/15/2022 | | s | | 3,900 | D | \$0.531 | 3,349,227(1 | L) | I | By SymBiosis LLC | |
| | | | | | curities Acqu IIs, warrants, | | | | | | ed | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date if any (Month/Day/Ye | 4. Transaction Code (Instr | 5. Number of Derivative | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | isable and 7. Title and Amount of Securities Underlying | | | Number of ivative curities neficially rned | 10. Ownership Form: Direct (D) or Indirect | Beneficial Ownership | |

| Security (Instr. 3) | or Exercise Price of Derivative Security | (Month/Day/Year) | if any (Month/Day/Year) | | | Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | (Month/Day/Year) | | Derivative Security (Instr. 3 and 4) | | Security (Instr. 5) | Reported | Form: Direct (D) | Beneficial Ownership (Instr. 4) | |
|---------------------|---|------------------|----------------------------|------|---|--|-----|---------------------|--------------------|---|-------------------------------------|------------------------|------------------------------|---------------------|---------------------------------------|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | | |
| | | | | | | | | | | | | | | | | |

Explanation of Responses:

1. The shares are directly held by SymBiosis, LLC.

<u>/s/ Chidozie Ugwumba</u> ** Signature of Reporting Person

<u>11/14/2022</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.